Work

The dipeptidyl peptidase‐4 inhibitor linagliptin lowers postprandial glucose and improves measures of β ‐cell function in type 2 diabetes

Year: 2014

Type: article

Source: Diabetes Obesity and Metabolism

DOI: 10.1111/dom.12312

Authors: T. Heise, M. Larbig, S. Patel, T. Seck, U. Hehnke, H.‐J. Woerle, K. Dugi

Institutions: Profil Institute for Metabolic Research, Boehringer Ingelheim (Germany), Boehringer Ingelheim (United Kingdom)

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Roche

OpenAlex ID: W1908117496

FWCI: 1.704

Cites: 13

Cited by: 14

Related to: 10